WithdrawnInterventionalEarly Phase 1Last updated Oct 11, 2017

CYP2C19 Genotype Predictor of Gastric Acid Suppression

CYP2C19 Genotype as a Predictor of Gastric Acid Suppression and Healing of Erosive Esophagitis

Overview

ClinicalTrials.gov ID: NCT01824199
Lead Sponsor: Mayo ClinicOTHER
Brief Summary: If CYP2C19 genotype can predict the efficacy of healing erosive esophagitis and gastric acid secretion in patients taking once a day omeprazole.
Study Type: Interventional

Status

Overall Status: Withdrawn
Start Date: Mar 2013Estimated
Primary Completion Date: Nov 2016Actual
Completion Date: Nov 2016Actual

Study Record Dates

First Submitted: Mar 27, 2013
First Submitted that Met QC Criteria: Apr 1, 2013
First Posted: Apr 4, 2013Estimated
Last Update Submitted that Met QC Criteria: Oct 9, 2017
Last Update Posted: Oct 11, 2017Actual
Last Verified: Oct 2017

NCT00537732Terminated

Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing

NCT02299687Completed

Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole

NCT00854451Completed

Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection

NCT01077076Completed

Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)

NCT03980496Completed

Effects of Different Omeprazole Dosing on Gastric pH in Non-variceal Upper Gastrointestinal Bleeding

NCT01008696Completed

An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis